ASKA Pharmaceutical Co.

Kawasaki, Japan

ASKA Pharmaceutical Co.

Kawasaki, Japan
SEARCH FILTERS
Time filter
Source Type

Patent
Hisamitsu Pharmaceutical and ASKA Pharmaceutical Co. | Date: 2017-09-06

The present invention provides a microneedles device comprising: a substrate; a microneedle disposed on the substrate; and a coating layer formed on the microneedle; in which the coating layer comprises a recombinant follicle-stimulating hormone, arginine, and glycerin, in the coating layer, the mass of arginine is 0.07 to 0.75-fold of the mass of the recombinant follicle-stimulating hormone and the mass of glycerin is 0.1 to 2.75-fold of the mass of the recombinant follicle-stimulating hormone.


Patent
Lintec Corporation and ASKA Pharmaceutical Co. | Date: 2013-01-30

The present invention relates to a solidpreparation having an easily controllable elution property of a drug, and a method for improving dissolution of a drug. A solid preparation 1 comprises a drug-containing unit 2 containing a drug, a gel-forming layer 4 for covering the drug-containing unit 2 and forming a gel by water absorption, and an intermediate layer 3 interposed between the drug-containing unit 2 and the gel-forming layer 4. The elution property of the drug is improved by forming a plurality of pores extending from a surface of the gel-forming layer toward the intermediate layer in the gel-forming layer 4. The gel-forming layer 4 may be covered with an anti-adhesive layer 5. The anti-adhesive layer 5 may have a pore 6 extending from a surface thereof and communicating with the pore of the gel-forming layer. The drug-containing unit 2 may contain a cationic or basic drug. The gel-forming layer 4 may contain an anionic or acidic polymer.


Patent
Lintec Corporation and ASKA Pharmaceutical Co. | Date: 2013-01-30

The present invention relates to a solidpreparation having an easily controllable elution property of a drug, and a method for improving dissolution of a drug. A solid preparation 1 comprises a drug-containing unit 2 containing a drug, and a gel-forming layer 4 for covering the drug-containing unit 2 and forming a gel by water absorption, and optionally an intermediate layer 3 interposed between the drug-containing unit 2 and the gel-forming layer 4. The solid preparation 1 improves the elution property of the drug by incorporating an effervescent agent (e.g., sodium hydrogencarbonate) into the drug-containing unit 2 and/or the intermediate layer 3. The drug-containing unit 2 may contain a cationic or basic drug. The gel-forming layer 4 may contain an anionic or acidic polymer. The gel-forming layer 4 may be covered with a surface layer (anti-adhesive layer) 5.


Patent
INC Research, Hitachi Ltd., Care Network and Aska Pharmaceutical Co. | Date: 2013-01-02

Demyelinated axons were remyelinated in the demyelinated rat model by collecting bone marrow cells from mouse bone marrow and transplanting the mononuclear cell fraction separated from these bone marrow cells.


Patent
INC Research, Care Network and Aska Pharmaceutical Co. | Date: 2015-05-28

Demyelinated axons were remyelinated in the demyelinated rat model by collecting bone marrow cells from mouse bone marrow and transplanting the mononuclear cell fraction separated from these bone marrow cells.


Patent
ASKA Pharmaceutical Co. | Date: 2013-05-22

Crystals are obtained by heating an aqueous suspension of 2-(3,4-dichlorobenzyl)-5-methyl-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidine-6-carboxylic acid. Novel crystals are obtained by adjusting the heating temperature and/or duration.


Patent
ASKA Pharmaceutical Co. | Date: 2013-04-10

A heterocyclic compound useful as an antiallergic agent is provided. A compound represented by the following formula (1) or a salt thereof:^(1) is a carbonyl group or an alkylene group; R^(2a) and R^(2b) are an alkyl group, a cycloalkyl group, an aryl group, or a heterocyclic group; X is an oxygen atom or a sulfur atom; Z is a hydroxyl group, an alkoxy group, a cycloalkyloxy group, an aryloxy group, an aralkyloxy group, an amino group, or an N-substituted amino group; and n is 0 or 1; with the proviso that when the ring A is a benzene ring or when the ring B is a piperazine ring, R^(1) is an alkylene group which may have a substituent.


Patent
ASKA Pharmaceutical Co. | Date: 2014-07-31

The invention discloses quinoxaline derivatives or salts thereof having PDE9-inhibiting activity and being useful as treating agent of dysuria and the like, which are represented by the formula (I) in the formula,


Patent
ASKA Pharmaceutical Co. | Date: 2014-03-26

The invention provides a crystal of 2-(3,4-dichlorobenzyl)-5-methyl-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidine-6-carboxylic acid (which has the chemical structure shown below) and a mixed crystal comprising such a crystal. The invention also provides methods of producing such crystals, pharmaceutical compositions comprising such crystals, and methods of modulating phosphodiesterase-9 activity and treating disorders such as overactive bladder syndrome by administration of an effective amount of the crystals.


Patent
ASKA Pharmaceutical Co. | Date: 2015-03-18

The invention discloses quinoxaline derivatives or salts thereof having PDE9-inhibiting activity and being useful as treating agent of dysuria and the like, which are represented by the formula (I)R^(1) and R^(2) each independently are hydrogen or C_(1-6) alkyl;R^(3) is C_(1-9) alkyl or C_(2-9) alkenyl each of which may be substituted with carboxy or C_(1-6) alkoxycarbonyl;R^(4) is hydrogen;R^(5) and R^(8) are hydrogen;R^(6) and R^(7) each independently are hydrogen; C_(1-6) alkyl or C_(1-6) alkoxy each of which is optionally substituted with halogen;X is O;A^(1), A^(2) and A^(3) are C,or a salt thereof.

Loading ASKA Pharmaceutical Co. collaborators
Loading ASKA Pharmaceutical Co. collaborators